Biotech Values

[Whalatane]

UNCY HC Wainwright & Co. analyst Ed Arce maintains Unicycive Therapeutics ( UNCY ) with a Buy and raises the price target from $4 to $7.5.....!!!! currently trading around .64 c

PDUFA date is June 28 and unless they do a reverse split by early May , Co will lose Naz compliance early July
UNCY's OLC will be 1/3 rd of the cost of ARDX's Xphozah and more effective at lowering serum pho . One small pill swallowed with each meal...vs the several large generic binder pills most dialysis patents must crush or chew with each meal now .

Co only has exclusivity for around 6 yrs assuming FDA approval , will enter TDAPA and probably receive declining revenue per script after the first 2-3 yrs

JMO
Kiwi